☆ 4.7 Article

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer

SCIENTIFIC REPORTS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer

Mayu Ibusuki et al.

Summary: This study evaluated the efficacy and safety of modified gemcitabine plus nab-paclitaxel for older patients with pancreatic cancer. Results showed good efficacy with acceptable toxicity, with a median overall survival of 15.4 months and progression-free survival of 5.9 months in 34 patients.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas

Martina Catalano et al.

Summary: The combination of nab-paclitaxel and gemcitabine has shown greater efficacy in treating metastatic pancreatic cancer patients compared to gemcitabine alone but with a higher risk of chemotherapy-induced peripheral neuropathy (CINP). Patients experiencing CINP may have a more favorable outcome, with higher disease control rates and prolonged median survival than those without neuropathy.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

Martina Catalano et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Add to Collection

Article Gastroenterology & Hepatology

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer

Hasan Rehman et al.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Epidemiology and burden of pancreatic cancer

Patrick Maisonneuve

PRESSE MEDICALE (2019)

Add to Collection

Article Oncology

P-065A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study

J Nakazawa et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Oncology

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

J. Ferlay et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Oncology

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo

M. M. Vickers et al.

EUROPEAN JOURNAL OF CANCER (2012)

Add to Collection

Review Oncology

Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy

Yousuke Nakai et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Surgery

Pancreatic Resection In Octogenarians

Jeffrey M. Hardacre et al.

JOURNAL OF SURGICAL RESEARCH (2009)

Add to Collection

Article Gastroenterology & Hepatology

Utilization and Determinants of Adjuvant Therapy Among Older Patients Who Receive Curative Surgery for Pancreatic Cancer

Jessica A. Davila et al.

PANCREAS (2009)

Add to Collection

Review Oncology

Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: An observational study

Christophe Locher et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)

Add to Collection

Article Gastroenterology & Hepatology

Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer

Raphael Marechal et al.

PANCREAS (2008)

Add to Collection

Article Gastroenterology & Hepatology

Outcome after pancreaticoduodenectomy for cancer in elderly patients

Radu Scurtu et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2006)

Add to Collection

Review Geriatrics & Gerontology

Current treatment strategies for pancreatic cancer in the elderly

Keiji Hanada et al.

DRUGS & AGING (2006)

Add to Collection

Review Oncology

Geriatric assessment and comorbidity

AV Rao et al.

SEMINARS IN ONCOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.